Acrivon Therapeutics, Inc. SEC Filings

Acrivon Therapeutics insiders reported an internal share disposition related to restricted stock unit vesting. On 08/21/2025, President and CEO Dr. Peter Blume-Jensen had 19,905 common shares dispositioned at $1.32 per share; the filing states these shares were withheld by the issuer to satisfy mandatory tax withholding on vested restricted stock units. After the transaction Dr. Blume-Jensen is reported to beneficially own 2,126,440 shares (direct). The filing also shows 315,196 common shares held indirectly by EVP Dr. Kristina Masson. Both reporting persons are officers and directors and are spouses; each disclaims beneficial ownership of the other’s holdings except to the extent of pecuniary interest. The Form 4 is signed by an attorney-in-fact on behalf of both reporting persons.

Acrivon Therapeutics insider sale reported on Form 4. Katharine Peterson, Chief Accounting Officer, recorded a transaction dated 08/14/2025 disclosing a disposition of 99 shares of Acrivon Therapeutics common stock at a price of $1.39 per share. Following the reported sale, Ms. Peterson beneficially owns 4,221 shares, held directly. The filing states the 99 shares were withheld by the issuer to satisfy mandatory tax withholding upon RSU vesting and is signed by an attorney-in-fact on 08/18/2025.

Mary Miller, Chief Legal Officer of Acrivon Therapeutics, Inc. (ACRV), reported a transaction on 08/14/2025 involving the company’s common stock. The filing shows 184 shares were disposed at a price of $1.39 per share.

The form states these shares were withheld by the issuer to satisfy a mandatory tax withholding obligation upon the vesting of restricted stock units. After the withholding, Ms. Miller beneficially owns 35,581 shares directly. The Form 4 was signed by an attorney-in-fact on 08/18/2025.

Erick Gamelin, Chief Development Officer of Acrivon Therapeutics, reported a routine withholding of 403 shares of Common Stock on 08/14/2025 to satisfy mandatory tax withholding when restricted stock units vested. The withheld shares were disposed at a reported price of $1.39 per share. After the transaction, Mr. Gamelin beneficially owns 15,686 shares of ACRV common stock. The Form 4 was signed by an attorney-in-fact on 08/18/2025. The filing notes the withholding was to cover taxes tied to RSU vesting.

Acrivon Therapeutics insider transaction summary: Eric Devroe, Chief Operating Officer of Acrivon Therapeutics, reported a single Form 4 transaction. On 08/14/2025 the reporting person had 613 shares withheld at a price of $1.39 per share as a result of tax withholding tied to the vesting of restricted stock units. After this withholding disposition, the reporting person beneficially owns 65,921 shares of Acrivon common stock, held directly. The Form 4 was signed by an attorney-in-fact on 08/18/2025. The filing notes the withholding was to satisfy mandatory tax obligations and includes a Power of Attorney exhibit.

Acrivon Therapeutics insiders reported routine post-vesting share dispositions on 08/14/2025. The Form 4 shows that restricted stock units were treated by the issuer to cover mandatory tax withholding: 59,766 shares were withheld at an effective price of $1.39, recorded as a disposition. After that transaction, Peter Blume-Jensen is shown as beneficially owning 2,146,345 shares (direct) and 315,196 shares (indirect) attributable to spouse holdings. A separate small disposition of 490 shares at $1.39 is reported as indirect ownership. Both Dr. Blume-Jensen (President and CEO) and Dr. Kristina Masson (EVP, Business Operations) are listed as reporting persons and each signed via attorney-in-fact on 08/18/2025.

Acrivon Therapeutics (ACRV) presented interim financials and clinical progress through June 30, 2025. The company recorded a six-month net loss of $40.7 million, bringing an accumulated deficit to $237.7 million, and reported cash, cash equivalents and investments of $147.6 million, which management says funds operations into the second quarter of 2027. Acrivon remains pre-revenue and continues to invest heavily in R&D.

Clinically, ACR-368 is in a registrational-intent Phase 2 program for endometrial cancer using the proprietary OncoSignature biomarker; an interim cohort of OncoSignature-positive patients showed a 35% confirmed overall response rate and tumor shrinkage in 80% of patients. ACR-2316 is in Phase 1 with early target engagement and a confirmed partial response observed at Dose Level 3. The company retains licensed rights to prexasertib under a Lilly agreement with up to $168 million in milestone payments and tiered royalties up to 10%.

This Schedule 13G/A reports that Sands Capital Life Sciences Pulse Fund II, L.P., Sands Capital Alternatives, LLC and Frank M. Sands jointly beneficially own 2,122,605 shares of Acrivon Therapeutics common stock, representing 6.8% of the outstanding shares based on 31,355,361 shares reported by the issuer. The filing shows no sole voting or dispositive power and indicates shared voting and dispositive power over the reported shares, consistent with a passive investor position.

The filing names the reporting entities, identifies their places of organization (Cayman Islands, Delaware and United States), provides the issuer's principal office address, and includes a certification that the securities were not acquired to change or influence control of the issuer.